Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 682M 599M 566M 515M 965M 65.41B 972M 6.77B 2.62B 33.42B 2.56B 2.51B 107B P/E 2026 *
3.38x
P/E 2027 * 3.14x
Enterprise Value 682M 599M 566M 515M 965M 65.41B 972M 6.77B 2.62B 33.42B 2.56B 2.51B 107B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 1.38x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-1.43%
1 week-5.28%
Current month-2.82%
1 month-5.92%
3 months+7.55%
6 months+29.47%
Current year+22.55%
1 week 4.05
Extreme 4.05
4.6
1 month 3.94
Extreme 3.94
4.6
Current year 2.95
Extreme 2.95
5.78
1 year 1.29
Extreme 1.29
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 19/07/2026
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Free

Director

3,694 0.0022%
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%-5.28%+225.20%-56.20% 682M
+0.54%+1.30%+91.73%+40.57% 367B
+0.78%+3.97%+27.12%-14.58% 66.89B
-1.15%+1.29%+53.98%+192.88% 12.93B
+0.24%+0.49%-1.88%-16.04% 7.54B
-1.30%-2.32%-27.85%-11.12% 4.38B
-1.33%-2.37%-37.20%+5.00% 4.07B
-4.23%+2.14%-30.63%-11.67% 3.02B
-1.46%+1.57%-9.58%+49.37% 2.48B
-2.18%-0.66%-22.30%-33.51% 1.91B
Average -1.17%-0.37%+26.86%+14.47% 47.1B
Weighted average by Cap. +0.33%+1.56%+76.20%+34.49%

Financials

2026 *2027 *
Net sales 471M 414M 391M 356M 667M 45.18B 671M 4.68B 1.81B 23.08B 1.77B 1.73B 74.19B 494M 434M 409M 373M 698M 47.35B 703M 4.9B 1.9B 24.19B 1.85B 1.81B 77.75B
Net income 203M 178M 168M 154M 287M 19.48B 289M 2.02B 781M 9.95B 763M 747M 31.99B 220M 193M 182M 166M 311M 21.07B 313M 2.18B 845M 10.77B 826M 808M 34.6B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
25/09/26 US$4.130 -1.43% 1,319,663
24/09/26 US$4.190 -1.87% 1,746,254
23/09/26 US$4.270 -5.64% 1,657,624
22/09/26 US$4.525 +2.61% 3,427,965
21/09/26 US$4.410 +1.15% 2,414,989
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.130USD
Average target price
6.100USD
Spread / Average Target
+47.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock